{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:07:44Z","timestamp":1746806864774,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After over a hundred years of research, the question whether the symptoms of schizophrenia are rather trait-like (being a relatively stable quality of individuals) or state-like (being substance to change) is still unanswered. To assess the trait and the state component in patients with acute schizophrenia, one group receiving antipsychotic treatment, the other not. Data from four phase II\/III, 6-week, randomized, double-blind, placebo-controlled trials of similar design that included patients with acute exacerbation of schizophrenia were pooled. In every trial, one treatment group received a third-generation antipsychotic, cariprazine, and the other group placebo. To assess symptoms of schizophrenia, the Positive and Negative Symptom Scale (PANSS) was applied. Further analyses were conducted using the five subscales as proposed by Wallwork and colleagues. A latent state\u2013trait (LST) model was developed to estimate the trait and state components of the total variance of the observed scores. All symptom dimensions behaved more in a trait-like manner. The proportions of all sources of variability changed over the course of the observational period, with a bent around weeks 3 and 4. Visually inspected, no major differences were found between the two treatment groups regarding the LST structure of symptom dimensions. This high proportion of inter-individual stability may represent an inherent part of symptomatology that behaves independently from treatment status.<\/jats:p>","DOI":"10.1007\/s00406-024-01790-3","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T17:01:35Z","timestamp":1711731695000},"page":"1333-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing the latent state\u2013trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia"],"prefix":"10.1007","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-5782","authenticated-orcid":false,"given":"Jana S.","family":"Kr\u00fcckl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1roly","family":"Acsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-4852","authenticated-orcid":false,"given":"Zs\u00f3fia B.","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-3651","authenticated-orcid":false,"given":"Julian","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2039-2262","authenticated-orcid":false,"given":"Roselind","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-6533","authenticated-orcid":false,"given":"Undine E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gota","family":"Barab\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-9008","authenticated-orcid":false,"given":"Christian G.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"Suppl 4","key":"1790_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00014180","volume":"249","author":"H H\u00e4fner","year":"1999","unstructured":"H\u00e4fner H, An Der Heiden W (1999) The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):14\u201326","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1790_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0920-9964(96)00087-4","volume":"23","author":"SK Schultz","year":"1997","unstructured":"Schultz SK, Miller DD, Oliver SE et al (1997) The life course of schizophrenia: age and symptom dimensions. Schizophr Res 23:15\u201323. https:\/\/doi.org\/10.1016\/S0920-9964(96)00087-4","journal-title":"Schizophr Res"},{"key":"1790_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0920-9964(97)00113-8","volume":"25","author":"G Huber","year":"1997","unstructured":"Huber G (1997) The heterogeneous course of schizophrenia. Schizophr Res 25:177\u2013185","journal-title":"Schizophr Res"},{"key":"1790_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/ijnp\/pyz053","volume":"22","author":"KN Fountoulakis","year":"2019","unstructured":"Fountoulakis KN, Dragioti E, Theofilidis AT et al (2019) Staging of Schizophrenia with the Use of PANSS: an international multi-center study. Int J Neuropsychopharmacol 22:681\u2013697. https:\/\/doi.org\/10.1093\/ijnp\/pyz053","journal-title":"Int J Neuropsychopharmacol"},{"key":"1790_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1192\/bjp.136.5.413","volume":"136","author":"L Ciompi","year":"1980","unstructured":"Ciompi L (1980) Three lectures on schizophrenia, the natural history of schizophrenia in the long term. Br J Psychiatry 136:413\u2013420","journal-title":"Br J Psychiatry"},{"key":"1790_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/schbul\/sbt069","volume":"40","author":"J Chiappelli","year":"2014","unstructured":"Chiappelli J, Nugent KL, Thangavelu K et al (2014) Assessment of trait and state aspects of depression in schizophrenia. Schizophr Bull 40:681\u2013697. https:\/\/doi.org\/10.1093\/schbul\/sbt069","journal-title":"Schizophr Bull"},{"key":"1790_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.schres.2014.11.027","volume":"161","author":"A Maat","year":"2015","unstructured":"Maat A, van Montfort SJT, de Nijs J et al (2015) Emotion processing in schizophrenia is state and trait dependent. Schizophr Res 161:392\u2013398. https:\/\/doi.org\/10.1016\/j.schres.2014.11.027","journal-title":"Schizophr Res"},{"key":"1790_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040672","volume":"7","author":"C Yan","year":"2012","unstructured":"Yan C, Cao Y, Zhang Y et al (2012) Trait and state positive emotional experience in schizophrenia: a meta-analysis. PLoS ONE 7:e40672. https:\/\/doi.org\/10.1371\/journal.pone.0040672","journal-title":"PLoS ONE"},{"key":"1790_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1744-859X-8-22","volume":"8","author":"L Pelizza","year":"2009","unstructured":"Pelizza L, Ferrari A (2009) Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry 8:22. https:\/\/doi.org\/10.1186\/1744-859X-8-22","journal-title":"Ann Gen Psychiatry"},{"key":"1790_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/08039488.2021.1981436","volume":"76","author":"T Fagerberg","year":"2022","unstructured":"Fagerberg T, S\u00f6derman E, Gustavsson JP et al (2022) Thirteen-year follow-up of long-term treated psychotic disorder: personality aspects. Nord J Psychiatry 76:386\u2013393. https:\/\/doi.org\/10.1080\/08039488.2021.1981436","journal-title":"Nord J Psychiatry"},{"key":"1790_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1017\/S0033291703008225","volume":"33","author":"P Whitty","year":"2003","unstructured":"Whitty P, Clarke M, Browne S et al (2003) Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol Med 33:1479\u20131484. https:\/\/doi.org\/10.1017\/S0033291703008225","journal-title":"Psychol Med"},{"key":"1790_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.psychres.2008.02.010","volume":"166","author":"G Loas","year":"2009","unstructured":"Loas G, Monestes JL, Ingelaere A et al (2009) Stability and relationships between trait or state anhedonia and schizophrenic symptoms in schizophrenia: a 13-year follow-up study. Psychiatry Res 166:132\u2013140. https:\/\/doi.org\/10.1016\/j.psychres.2008.02.010","journal-title":"Psychiatry Res"},{"key":"1790_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/(sici)1099-0984(199909\/10)13:5<389::aid-per361>3.0.co;2-a","volume":"13","author":"R Steyer","year":"1999","unstructured":"Steyer R, Schmitt M, Michael E (1999) Latent state-trait theory and research in personality and individual differences. Eur J Pers 13:389\u2013408. https:\/\/doi.org\/10.1002\/(sici)1099-0984(199909\/10)13:5%3c389::aid-per361%3e3.0.co;2-a","journal-title":"Eur J Pers"},{"key":"1790_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-clinpsy-032813-153719","volume":"11","author":"R Steyer","year":"2015","unstructured":"Steyer R, Mayer A, Geiser C, Cole DA (2015) A theory of states and traits\u2014revised. Annu Rev Clin Psychol 11:71\u201398. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032813-153719","journal-title":"Annu Rev Clin Psychol"},{"key":"1790_CR15","first-page":"79","volume":"8","author":"R Steyer","year":"1992","unstructured":"Steyer R, Ferring D, Schmitt M (1992) States and traits in psychological assessment. Eur J Psychol Assess 8:79\u201398","journal-title":"Eur J Psychol Assess"},{"key":"1790_CR16","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1038\/s41598-022-10207-x","volume":"12","author":"L Hochstrasser","year":"2022","unstructured":"Hochstrasser L, Studerus E, Riecher-R\u00f6ssler A et al (2022) Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. Sci Rep 12:6652. https:\/\/doi.org\/10.1038\/s41598-022-10207-x","journal-title":"Sci Rep"},{"key":"1790_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.schres.2013.07.042","volume":"150","author":"W R\u00f6ssler","year":"2013","unstructured":"R\u00f6ssler W, Hengartner MP, Ajdacic-Gross V et al (2013) Deconstructing sub-clinical psychosis into latent-state and trait variables over a 30-year time span. Schizophr Res 150:197\u2013204. https:\/\/doi.org\/10.1016\/j.schres.2013.07.042","journal-title":"Schizophr Res"},{"key":"1790_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 382:951\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"The Lancet"},{"key":"1790_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K et al (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet 379:2063\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(12)60239-6","journal-title":"The Lancet"},{"key":"1790_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1017\/S0033291710002035","volume":"41","author":"TR Marques","year":"2011","unstructured":"Marques TR, Arenovich T, Agid O et al (2011) The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 41:1481\u20131488. https:\/\/doi.org\/10.1017\/S0033291710002035","journal-title":"Psychol Med"},{"key":"1790_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/070674371506001107","volume":"60","author":"J Lee","year":"2015","unstructured":"Lee J, Takeuchi H, Fervaha G et al (2015) Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry 60:515\u2013522","journal-title":"Can J Psychiatry"},{"key":"1790_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.schres.2011.09.006","volume":"133","author":"WC Chang","year":"2011","unstructured":"Chang WC, Hui CLM, Tang JYM et al (2011) Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res 133:22\u201328. https:\/\/doi.org\/10.1016\/j.schres.2011.09.006","journal-title":"Schizophr Res"},{"key":"1790_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2012.08.017","volume":"142","author":"N Boonstra","year":"2012","unstructured":"Boonstra N, Klaassen R, Sytema S et al (2012) Duration of untreated psychosis and negative symptoms\u2014a systematic review and meta-analysis of individual patient data. Schizophr Res 142:12\u201319","journal-title":"Schizophr Res"},{"key":"1790_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","volume":"63","author":"MI Krakowski","year":"2006","unstructured":"Krakowski MI, Czobor P, Citrome L et al (2006) Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 63:622\u2013629. https:\/\/doi.org\/10.1001\/archpsyc.63.6.622","journal-title":"Arch Gen Psychiatry"},{"key":"1790_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","volume":"2","author":"S Durgam","year":"2016","unstructured":"Durgam S, Litman RE, Papadakis K et al (2016) Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol 2:61\u201368. https:\/\/doi.org\/10.1097\/YIC.0000000000000110","journal-title":"Int Clin Psychopharmacol"},{"key":"1790_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","volume":"152","author":"S Durgam","year":"2014","unstructured":"Durgam S, Starace A, Li D et al (2014) An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 152:450\u2013457. https:\/\/doi.org\/10.1016\/j.schres.2013.11.041","journal-title":"Schizophr Res"},{"key":"1790_CR27","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","volume":"76","author":"S Durgam","year":"2015","unstructured":"Durgam S, Cutler AJ, Lu K et al (2015) Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 76:e1574\u2013e1582. https:\/\/doi.org\/10.4088\/JCP.15m09997","journal-title":"J Clin Psychiatry"},{"key":"1790_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","volume":"35","author":"JM Kane","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y et al (2015) Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 35:367\u2013373. https:\/\/doi.org\/10.1097\/JCP.0000000000000346","journal-title":"J Clin Psychopharmacol"},{"key":"1790_CR29","unstructured":"American Psychiatric Association (1999) American Psychiatric Association: diagnostic and statistical manual of mental disorders fourth edition"},{"key":"1790_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538\u2013546. https:\/\/doi.org\/10.4088\/JCP.v58n1205","journal-title":"J Clin Psychiatry"},{"key":"1790_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0920-9964(94)00041-6","volume":"14","author":"JP Lindenmayer","year":"1995","unstructured":"Lindenmayer JP, Grochowski S, Hyman RB (1995) Five factor model of schizophrenia: replication across samples. Schizophr Res 14:229\u2013234. https:\/\/doi.org\/10.1016\/0920-9964(94)00041-6","journal-title":"Schizophr Res"},{"key":"1790_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","volume":"137","author":"RS Wallwork","year":"2012","unstructured":"Wallwork RS, Fortgang R, Hashimoto R et al (2012) Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res 137:246\u2013250. https:\/\/doi.org\/10.1016\/j.schres.2012.01.031","journal-title":"Schizophr Res"},{"key":"1790_CR33","doi-asserted-by":"publisher","DOI":"10.4324\/9781315871318","volume-title":"Longitudinal structural equation modeling: a comprehensive introduction","author":"JT Newsom","year":"2015","unstructured":"Newsom JT (2015) Longitudinal structural equation modeling: a comprehensive introduction. Routledge, New York"},{"key":"1790_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3758\/s13428-014-0457-z","volume":"47","author":"C Geiser","year":"2015","unstructured":"Geiser C, Keller BT, Lockhart G et al (2015) Distinguishing state variability from trait change in longitudinal data: the role of measurement (non)invariance in latent state-trait analyses. Behav Res Methods 47:172\u2013203. https:\/\/doi.org\/10.3758\/s13428-014-0457-z","journal-title":"Behav Res Methods"},{"key":"1790_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i02","volume":"48","author":"Y Rosseel","year":"2012","unstructured":"Rosseel Y (2012) Lavaan: an R package for structural equation modeling. J Stat Softw 48:1\u201336. https:\/\/doi.org\/10.18637\/jss.v048.i02","journal-title":"J Stat Softw"},{"key":"1790_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1192\/bjp.161.4.501","volume":"161","author":"MS Humphreys","year":"1992","unstructured":"Humphreys MS, Johnstone EC, MacMillan JF, Taylor PJ (1992) Dangerous behaviour preceding first admissions for schizophrenia. Br J Psychiatry 161:501\u2013505. https:\/\/doi.org\/10.1192\/bjp.161.4.501","journal-title":"Br J Psychiatry"},{"key":"1790_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2011.12.002","volume":"134","author":"CG Huber","year":"2012","unstructured":"Huber CG, Sch\u00f6ttle D, Lambert M et al (2012) Brief psychiatric rating scale\u2014excited component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis. Schizophr Res 134:273\u2013278. https:\/\/doi.org\/10.1016\/j.schres.2011.12.002","journal-title":"Schizophr Res"},{"key":"1790_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0920-9964(99)00205-4","volume":"45","author":"D Baynes","year":"2000","unstructured":"Baynes D, Mulholland C, Cooper SJ et al (2000) Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 45:47\u201356. https:\/\/doi.org\/10.1016\/S0920-9964(99)00205-4","journal-title":"Schizophr Res"},{"key":"1790_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","volume":"24","author":"MJ Millan","year":"2014","unstructured":"Millan MJ, Fone K, Steckler T, Horan WP (2014) Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24:645\u2013692. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"1790_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1017\/S0033291708003814","volume":"39","author":"J van Os","year":"2009","unstructured":"van Os J, Linscott RJ, Myin-Germeys I et al (2009) A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 39:179\u2013195. https:\/\/doi.org\/10.1017\/S0033291708003814","journal-title":"Psychol Med"},{"key":"1790_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/schbul\/sbw097","volume":"43","author":"R Upthegrove","year":"2017","unstructured":"Upthegrove R, Marwaha S, Birchwood M (2017) Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull 43:240\u2013244. https:\/\/doi.org\/10.1093\/schbul\/sbw097","journal-title":"Schizophr Bull"},{"key":"1790_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.schres.2017.07.035","volume":"193","author":"G van Rooijen","year":"2018","unstructured":"van Rooijen G, Isvoranu AM, Kruijt OH et al (2018) A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. Schizophr Res 193:232\u2013239. https:\/\/doi.org\/10.1016\/j.schres.2017.07.035","journal-title":"Schizophr Res"},{"key":"1790_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/schbul\/sbw095","volume":"43","author":"JTW Wigman","year":"2017","unstructured":"Wigman JTW, de Vos S, Wichers M et al (2017) A transdiagnostic network approach to psychosis. Schizophr Bull 43:122\u2013132. https:\/\/doi.org\/10.1093\/schbul\/sbw095","journal-title":"Schizophr Bull"},{"key":"1790_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2021.12.001","volume":"242","author":"TD Cannon","year":"2022","unstructured":"Cannon TD (2022) Psychosis, schizophrenia, and states vs. traits. Schizophr Res 242:12\u201314. https:\/\/doi.org\/10.1016\/j.schres.2021.12.001","journal-title":"Schizophr Res"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01790-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01790-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01790-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T10:07:23Z","timestamp":1724926043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01790-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01790-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"type":"print","value":"0940-1334"},{"type":"electronic","value":"1433-8491"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zs\u00f3fia Borb\u00e1la Dombi and \u00c1gota Barab\u00e1ssy are employees of Gedeon Richter Plc., originator of cariprazine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}